Literature DB >> 17118759

Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication.

Akihiro Abe1, Hitoshi Kiyoi, Manabu Ninomiya, Tomio Yamazaki, Takuhei Murase, Kazutaka Ozeki, Momoko Suzuki, Fumihiko Hayakawa, Akira Katsumi, Nobuhiko Emi, Tomoki Naoe.   

Abstract

We have established a stroma-dependent myelomonocytic cell line, NAMO-2, with FLT3 internal tandem duplication (FLT3/ITD). Leukemia cells from a patient with acute myelomonocytic leukemia were administered to form subcutaneous tumors in nude mice, which were maintained successively, although we failed to establish continuously growing cells from the original leukemia cell culture. In the cultures of cells from subcutaneous tumors, there were stroma cells that had originated from the nude mice and showed continuous growth. The leukemia cells showed continuous growth dependent on this stroma, and this cell line was named NAMO-2. Detection of FLT3/ITD by the reverse transcriptase polymerase chain reaction (PCR) and genomic PCR showed that NAMO-2 was homozygous for FLT3/ITD. Constitutive activation of FLT3 was detected by Western blotting, and the phosphorylation of Akt, MEK, and STAT5 was also observed. FLT3 kinase inhibitor AG1296 specifically inhibited cell growth. NAMO-2 provides a useful tool to analyze adherence-dependent survival signaling of leukemia with FLT3/ITD and a model for the screening of FLT3 kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118759     DOI: 10.1532/IJH97.06056

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  31 in total

Review 1.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

2.  Expression of the cell adhesion molecule E-cadherin by the human bone marrow stromal cells and its probable role in CD34(+) stem cell adhesion.

Authors:  K R Turel; S G Rao
Journal:  Cell Biol Int       Date:  1998       Impact factor: 3.612

3.  The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.

Authors:  Karsten Spiekermann; Ralf J Dirschinger; Ruth Schwab; Ksenia Bagrintseva; Florian Faber; Christian Buske; Susanne Schnittger; Louise M Kelly; D Gary Gilliland; Wolfgang Hiddemann
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

4.  Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts.

Authors:  G Marcucci; M P Strout; C D Bloomfield; M A Caligiuri
Journal:  Cancer Res       Date:  1998-02-15       Impact factor: 12.701

5.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Authors:  H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

Review 6.  FLT3 tyrosine kinase inhibitors.

Authors:  Mark Levis; Donald Small
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

7.  Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.

Authors:  Ryoichi Ono; Hideaki Nakajima; Katsutoshi Ozaki; Hidetoshi Kumagai; Toshiyuki Kawashima; Tomohiko Taki; Toshio Kitamura; Yasuhide Hayashi; Tetsuya Nosaka
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

8.  Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.

Authors:  Lisa J Robinson; Jia Xue; Seth J Corey
Journal:  Exp Hematol       Date:  2005-04       Impact factor: 3.084

9.  Osteoblastic cells regulate the haematopoietic stem cell niche.

Authors:  L M Calvi; G B Adams; K W Weibrecht; J M Weber; D P Olson; M C Knight; R P Martin; E Schipani; P Divieti; F R Bringhurst; L A Milner; H M Kronenberg; D T Scadden
Journal:  Nature       Date:  2003-10-23       Impact factor: 49.962

10.  Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche.

Authors:  Fumio Arai; Atsushi Hirao; Masako Ohmura; Hidetaka Sato; Sahoko Matsuoka; Keiyo Takubo; Keisuke Ito; Gou Young Koh; Toshio Suda
Journal:  Cell       Date:  2004-07-23       Impact factor: 41.582

View more
  1 in total

1.  The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells.

Authors:  Y Kuwatsuka; M Minami; Y Minami; K Sugimoto; F Hayakawa; Y Miyata; A Abe; D J Goff; H Kiyoi; T Naoe
Journal:  Blood Cancer J       Date:  2011-05-13       Impact factor: 11.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.